Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page
- Check7 days agoChange DetectedThe page now shows revision v3.5.4 instead of v3.5.3, indicating a new release of the page/template. No study data or content appears to be changed.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe ClinicalTrials.gov page revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded the MeSH term Malignant lymphoma, large B-cell, diffuse. Introduced a Resources section with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check65 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3.SummaryDifference0.0%

- Check72 days agoChange DetectedAdded new revision entry v3.4.3 with March 2026 dates; removed prior revision entry v3.4.2 and February 2026 dates.SummaryDifference0.3%

- Check79 days agoChange DetectedAdded Results Posted with primary and secondary outcomes (ORR, CRR, PFS, OS) and related dates, including Results First Submitted/Posted timestamps. Also attached the Study Protocol and Statistical Analysis Plan PDF.SummaryDifference1%

Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.